MRSA otorrhea: A case series and review of the literature

Ear, Nose and Throat Journal

Volumn 90, Issue 2, 2011, Pages 60-79

  Baugher, Katherine M ^a   Hemme, Troy Sommers ^a   Hawkshaw, Mary ^b   Sataloff, Robert T ^b  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME; COTRIMOXAZOLE; DEXAMETHASONE PLUS TOBRAMYCIN; EAR DROPS; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; FEMALE; HUMAN; MALE; MASTOIDECTOMY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MYRINGOTOMY; OTORRHEA; RETROSPECTIVE STUDY; TREATMENT DURATION;

EID: 84867380661     PISSN: 01455613     EISSN: None     Source Type: Journal    
DOI: 10.1177/014556131109000206     Document Type: Article

References (46)

1. Naseri I, Jerris RC, Sobol SE. Nationwide trends in pediatric Staphylococcus aureus head and neck infections. Arch Otolaryngol Head Neck Surg 2009; 135 (1): 14-16.
2. Marcinak JF, Frank AL. Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children. Expert Rev Anti Infect Ther 2006; 4 (1): 91-100.
3. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36 (2): 131-9.
4. Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: An emerging threat. Lancet Infect Dis 2005; 5 (5): 275-86.
5. Okuma K, Iwakawa K, Turnidge JD, et al. Dissemination of new methicillin-resistant Staphylococcus aureus clones in the community. J Clin Microbiol 2002; 40 (11): 4289-94.
6. Centers for Disease Control and Prevention. Community-associated MRSA information for clinicians. http://emergency.cdc.gov/disasters/disease/mrsaclinicians.asp Last accessed January 5, 2011.
7. Crawford SE, Daum RS. Epidemic community-associated methicillin-resistant Staphylococcus aureus: Modern times for an ancient pathogen. Pediatr Infect Dis J 2005; 24 (5): 459-60.
8. Kaplan SL. Community-acquired methicillin-resistant Staphylococcus aureus infections in children. Semin Pediatr Infect Dis 2006; 17 (3): 113-19.
9. Johnson MD, Decker CF. Antimicrobial agents in treatment of MRSA infections. Dis Mon 2008; 54 (12): 793-800.
10. Park DC, Lee SK, Cha CI, et al. Antimicrobial resistance of Staphylococcus from otorrhea in chronic suppurative otitis media and comparison with results of all isolated Staphylococci. Eur J Clin Microbiol Infect Dis 2008; 27 (7): 571-7.
11. Park MK, Jung MH, Kang HJ, et al. The changes of MRSA infections in chronic suppurative otitis media. Otolaryngol Head Neck Surg 2008; 139 (3): 395-8.
12. Al-Shawwa BA, Wegner D. Trimethoprim-sulfamethoxazole plus topical antibiotics as therapy for acute otitis media with otorrhea caused by community-acquired methicillin-resistant Staphylococcus aureus in children. Arch Otolaryngol Head Neck Surg 2005; 131 (9): 782-4.
13. Diekema DJ, Pfaller MA, Schmitz FJ, et al. SENTRY Participants Group. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl 2): S114-32.
14. Le J, Lieberman JM. Management of community-associated methicillin-resistant Staphylococcus aureus infections in children. Pharmacotherapy 2006; 26 (12): 1758-70.
15. Kim HB, Jang HC, Nam HJ, et al. In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: A nationwide survey. Antimicrob Agents Chemother 2004; 48 (4): 1124-7.
16. Grim SA, Rapp RP, Martin CA, Evans ME. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2005; 25 (2): 253-64.
17. Iyer S, Jones DH. Community-acquired methicillin-resistant Staphylococcus aureus skin infection: A retrospective analysis of clinical presentation and treatment of a local outbreak. J Am Acad Dermatol 2004; 50 (6): 854-8.
18. Hartnick CJ, Shott S, Willging JP, Myer CM III. Methicillin-resistant Staphylococcus aureus otorrhea after tympanostomy tube placement: An emerging concern. Arch Otolaryngol Head Neck Surg 2000; 126 (12): 1440-3.
19. Saunders JE, Raju RP, Boone J, Berryhill W. Current bacteriology of suppurative otitis: Resistant patterns and outcomes analysis. Otol Neurotol 2009; 30 (3): 339-43.
20. Hwang JH, Chu CK, Liu TC. Changes in bacteriology of discharging ears. J Laryngol Otol 2002; 116 (9): 686-9.
21. Hwang JH, Tsai HY, Liu TC. Community-acquired methicillin-resistant Staphylococcus aureus infections in discharging ears. Acta Otolaryngol 2002; 122 (8): 827-30.
22. Yeo SG, Park DC, Hong SM, et al. Bacteriology of chronic suppurative otitis media-a multicenter study. Acta Otolaryngol 2007; 127 (10): 1062-7.
23. Isaacson G, Aronoff SC. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae. Int J Pediatr Otorhinolaryngol 2008; 72 (5): 647-51.
24. Bouchillon SK, Johnson BM, Hoban DJ, et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: The PEARLS study 2001-2002. Int J Antimicrob Agents 2004; 24 (2): 119-24.
25. Weber PC, Roland PS, Hannley M, et al. The development of antibiotic resistant organisms with the use of ototopical medications. Otolaryngol Head Neck Surg 2004; 130 (3 Suppl): S89-94.
26. Kashiwamura M, Chida E, Matsumura M, et al. The efficacy of Burow's solution as an ear preparation for the treatment of chronic ear infections. Otol Neurotol 2004; 25 (1): 9-13.
27. Choi HG, Park KH, Park SN, et al. The appropriate medical management of methicillin-resistant Staphylococcus aureus in chronic suppurative otitis media. Acta Otolaryngol 2010; 130 (1): 42-6.
28. Nishiike S, Akisada T, Aihara T, et al. Examination of the effects of Burow's solution on intractable chronic suppurative ear disease. Practica Otothinolaryngol 2007; 100 (8): 649-53.
29. Howden BP, Grayson ML. Dumb and dumber-the potential waste of a useful antistaphylococcal agent: Emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 2006; 42 (3): 394-400.
30. Moellering RC Jr. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2008; 46 (7): 1032-7.
31. Jang CH, Song CH, Wang PC. Topical vancomycin for chronic suppurative otitis media with methicillin-resistant Staphylococcus aureus otorrhoea. J Laryngol Otol 2004; 118 (8): 645-7.
32. Lee SH, Lee JE, Baek WY, Lim JO. Regional delivery of vancomycin using pluronic F-127 to inhibit methicillin resistant Staphylococcus aureus (MRSA) growth in chronic otitis media in vitro and in vivo. J Control Release 2004; 96 (1): 1-7.
33. Lee SH, Park CW, Tae K, et al. Comparative analysis of therapeutic effect between topical vancomycin and systemic vancomycin in otorrhea by methicillin-resistant Staphylococcus aureus (MRSA) infection. Korean Journal of Otolarngology-Head and Neck Surgery 1999; 42 (6): 704-8.
34. Pan A, Lorenzotti S, Zoncada A. Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. Recent Pat Antiinfect Drug Discov 2008; 3 (1): 10-33.
35. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008; 46 (Suppl 5): S360-7.
36. Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. J Drugs Dermatol 2007; 6 (1): 97-103.
37. Jacqueline C, Caillon J, Le Mabecque V, et al. In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods. J Antimicrob Chemother 2003; 51 (4): 857-64.
38. Spellberg B, Yoo T, Bayer AS. Reversal of linezolid-associated cytopenias, but not peripheral neuropathy, by administration of vitamin B6. J Antimicrob Chemother 2004; 54 (4): 832-5.
39. Leonard SN, Cheung CM, Rybak MJ. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2008; 52 (8): 2974-6.
40. Smith K, Perez A, Ramage G, et al. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents 2009; 33 (4): 374-8.
41. Nichols RL, Graham DR, Barriere SL, et al. Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin Structure Infection Group. J Antimicrob Chemother 1999; 44 (2): 263-73.
42. Delgado G Jr., Neuhauser MM, Bearden DT, Danziger LH. Quinupristin-dalfopristin: An overview. Pharmacotherapy 2000; 20 (12): 1469-85.
43. Brook I. Current management of upper respiratory tract and head and neck infections. Eur Arch Otorhinolaryngol 2009; 266 (3): 315-23.
44. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: A Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62 (Suppl 1): i17-28.
45. Klein J, Chan S. Methicillin-resistant Staphylococcus aureus in middle ear fluid of children. Clin Pediatr (Phila) 2010; 49 (1): 66-8.
46. Jung H, Lee SK, Cha SH, et al. Current bacteriology of chronic otitis media with effusion: High rate of nosocomial infection and decreased antibiotic sensitivity. J Infect 2009; 59 (5): 308-16.